arrow
R

Rana R. McKay

University of California San Diego Moores Cancer Center
H指数:57
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer

吸烟、肿瘤遗传学与转移性前列腺癌患者预后的关联

2026-09-050
PRE
11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

11 OMNIVORE试验的长期随访:适应性纳武利尤单抗和伊匹木单抗在晚期肾细胞癌中的疗效(NCT03652142)

2026-09-020
OAAI
54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

54 转移性肾细胞癌中一线纳武利尤单抗联合伊匹木单抗治疗的原发进展性疾病与结局:一项真实世界IMDC分析

2026-09-020
OAAI
70 Lymphocyte Hsp70 is a Novel Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

70 淋巴细胞Hsp70是转移性肾细胞癌对免疫检查点抑制剂反应的新型预测生物标志物

2026-09-020
OAAI
22 Phase II Study of Cemiplimab ± Fianlimab Following SBRT for Oligometastatic Clear-Cell RCC (LAG-BOOST) (NCT07223541)

22 cemiplimab联合或不联合fianlimab在寡转移性透明细胞肾细胞癌SBRT后治疗的II期研究(LAG-BOOST)(NCT07223541)

2026-09-020
OAAI
75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

75 ARNT表达的相关转录特征及其对透明细胞肾细胞癌(ccRCC)生存结局的影响

2026-09-020
OAAI
51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

51 与肾细胞癌临床结局相关的耗竭CD8+ T细胞状态的发现

2026-09-020
OAAI
61 Differential Pattern of Disease Recurrence in Resected Renal Cell Carcinoma Patients Treated with Adjuvant Pembrolizumab Versus Observation: A Propensity Score-Weighted Analysis

61 接受辅助性帕博利珠单抗治疗与观察治疗的切除性肾细胞癌患者疾病复发的差异模式:一项倾向性评分加权分析

2026-09-020
OAAI
10 Outcomes of Patients with Renal Cell Carcinoma Achieving Pathologic Complete or Major Response After Consolidative Nephrectomy Following Immune Checkpoint Inhibitor Therapy

10 接受免疫检查点抑制剂治疗后进行巩固性肾切除术并达到病理完全或显著缓解的肾细胞癌患者的结局

2026-09-020
OAAI
88 PEAK-1 (NCT07011719): A Randomized, Double-Blind, Active-Control Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

PEAK-1 (NCT07011719):一项关于卡沙替法尼和卡博赞替尼与安慰剂和卡博赞替尼在晚期透明细胞肾细胞癌患者中进行的随机、双盲、活性对照III期试验

2026-09-020
OAAI
57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

57 TiNivo-2 III期试验的最终分析:替沃扎尼(Tivo)在转移性肾细胞癌(mRCC)患者中的长期结局

2026-09-020
OAAI
1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)

3 卡德拉替芬单药治疗透明细胞肾细胞癌患者的安全性特征:ARC-20研究(NCT05536141)的合并分析

2026-09-020
OAAI
8 Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)

8 单细胞转录组学分析揭示肾细胞癌(RCC)中与免疫检查点抑制(ICI)耐药性相关的组织驻留记忆耗竭型CD8+ T细胞特征

2026-09-020
OAAI